ALX ONCOLOGY HOLDINGS INC (ALXO:NASDAQ)
$1.8 0.1 (5.8824%)
Analysed ALX ONCOLOGY HOLDINGS INC (ALXO:NASDAQ) News Sources
ALX Oncology Appoints Jeff Knight as Chief Development and Operating Officer
13-04-2026
yahoo.com
ALDX Crashes 71% as FDA Issues Third CRL for Dry Eye Disease Drug NDA
18-03-2026
yahoo.com
CTMX Stock Rallies on Strong Phase I Colorectal Cancer Study Data
17-03-2026
yahoo.com
IBRX Stock Jumps on Progress in NK Cell Therapy Production
16-03-2026
yahoo.com
JNJ's Bladder Cancer Therapy Meets Key Goal in Early-Stage Study
16-03-2026
yahoo.com
Allogene Therapeutics Posts Narrower-Than-Expected Loss in Q4
13-03-2026
yahoo.com
ALX Oncology initiated with a Buy at UBS
07-03-2026
yahoo.com
LRMR Stock on the Move: What Sparked the 55% Jump in the Past Month?
06-03-2026
yahoo.com
Mirum Completes Enrollment & Screening in Liver Disease Studies
06-03-2026
yahoo.com
ALX Oncology Highlights $150M Raise, Evorpacept Breast Cancer Push and EGFR ADC ALX2004 Update
04-03-2026
marketbeat.com
What is the current price of ALX ONCOLOGY HOLDINGS INC (ALXO:NASDAQ)?
The current price of ALX ONCOLOGY HOLDINGS INC (ALXO:NASDAQ) is $1.8.
ALX ONCOLOGY HOLDINGS INC (ALXO:NASDAQ) absolute price change since previous trading day?
The absolute price change of ALX ONCOLOGY HOLDINGS INC (ALXO:NASDAQ) since the previous trading day is $0.1.
ALX ONCOLOGY HOLDINGS INC (ALXO:NASDAQ) percentage price change since previous trading day?
The percentage price change of ALX ONCOLOGY HOLDINGS INC (ALXO:NASDAQ) since the previous trading day is 5.8824%.
What is the most recent average sentiment score for ALX ONCOLOGY HOLDINGS INC (ALXO:NASDAQ)?
The most recent average sentiment score for ALX ONCOLOGY HOLDINGS INC (ALXO:NASDAQ) is 72 out of 100.
What is the most recent average sentiment for ALX ONCOLOGY HOLDINGS INC (ALXO:NASDAQ)?
The most recent sentiment for ALX ONCOLOGY HOLDINGS INC (ALXO:NASDAQ) is .
SEC-8K** Filing Available For ALX ONCOLOGY HOLDINGS INC (ALXO:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.